Ardelyx Inc. (ARDX) shares plummeted 7.12% in after-hours trading on Thursday following the release of its fourth quarter and full-year 2025 financial results.
The biopharmaceutical company reported quarterly earnings of $0.00 per share, which missed the analyst consensus estimate of $0.01 by 85.71%. This represents a 95% decrease compared to earnings of $0.02 per share from the same period last year. While quarterly sales of $125.215 million beat estimates, the significant earnings disappointment and a widening full-year net loss appear to have driven investor selling pressure.
According to the financial reports, Ardelyx's net loss for 2025 widened to $61.6 million from $39.1 million in 2024, indicating continued challenges in achieving profitability despite revenue growth from its key products.